This study aimed to determine antihyperglycemic therapy prescriptions for people living with T2D in a primary care setting and to study if there were differences in SGLT2i and GLP-1 RA prescription taking into account the presence of ASCVD or HF. The gene discussed is GLP1R; the disease is atherosclerosis.